Behavioral assessment in the African green monkey after MPTP administration

Neuromethods

Volumn 61, Issue , 2011, Pages 401-435

  Redmond Jr , D Eugene ^a  

^a NONE

Author keywords

African green monkey; Ethological; l DOPA; Long term effects; MPTP; Parkinson's; Ratings

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; AROUSAL; ARTICLE; BRUXISM; CATALEPSY; CHLOROCEBUS; CLIMBING; CONTROLLED STUDY; DOSE RESPONSE; DRINKING; DRUG DOSE COMPARISON; DRUG SENSITIVITY; DYSKINESIA; DYSTONIA; EATING; EATING DISORDER; EXPERIMENTAL MODEL; EYELID CLOSURE; EYELID REFLEX; FACIES; FEEDING BEHAVIOR; GROOMING; HEAD TREMOR; LIMB TREMOR; LOCOMOTION; MASTURBATION; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NONHUMAN; OBSERVER BIAS; OUTCOME ASSESSMENT; PARKINSON DISEASE; PENIS ERECTION; PHYSICAL MOBILITY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SCRATCHING; SEDATION; SENSITIVITY ANALYSIS; STEREOTYPY; TAIL FLAG; THREAT; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDITY; VIDEORECORDING; VOCALIZATION;

CERCOPITHECUS AETHIOPS; PRIMATES;

EID: 80054724514     PISSN: 08932336     EISSN: 19406045     Source Type: Book Series    
DOI: 10.1007/978-1-61779-298-4_21     Document Type: Article

References (124)

1. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatric Research 1: 249-154
2. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980 (Pubitemid 13189531)
3. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: Selective destruction of minergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proceedings of the National Academy of Science, USA 80: 4546-4550 (Pubitemid 13077876)
4. Langston JW, Forno LS, Rebert CS, and Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4- phenyl-1,2,5, 6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Research 292: 390-394 (Pubitemid 14190114)
5. Tetrud JW, Langston JW, Redmond DE, Jr., Roth RH, Sladek JR, Jr., Angel RW (1986) MPTP-induced tremor in human and nonhuman primates. Neurology 36: 308
6. Redmond DE, Jr., Sladek JR, Jr., Roth RH, Collier TJ, Elsworth JD, Deutch AY, Haber S (1986) Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1: 1125-1127
7. Deutch AY, Elsworth JD, Goldstein M, Fuxe K, Redmond DE, Jr., Sladek JR, Jr., Roth RH (1986) Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. Neuroscience Letters 68: 51-56 (Pubitemid 16064683)
8. Elsworth JD, Deutch AY, Redmond DE, Jr., Sladek JR, Jr., Roth RH (1987) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Research 415: 293-299 (Pubitemid 17100335)
9. Elsworth JD, Deutch AY, Redmond DE, Jr., Sladek JR, Jr., Roth RH (1987) Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in subregions of the primate substantia nigra and striatum. Life Sciences 40: 193-202 (Pubitemid 17215383)
10. Elsworth JD, Leahy DJ, Roth RH, Redmond DE, Jr. (1987) Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. Journal of Neural Transmission 68: 51-62
11. Elsworth JD, Deutch AY, Redmond DE, Jr., Taylor JR, Sladek JR, Jr., Roth RH (1989) Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine- treated primates: biochemical changes in striatal regions. Neuroscience 33: 323-331 (Pubitemid 20039715)
12. Elsworth JD, Taylor JR, Redmond DE, Jr., Collier TJ, Sladek JR, Roth RH (1989) Biochemical assessment of reversal of MPTP-induced parkinsonism following intrastriatal transplants of fetal substantia nigra in primates. Restorative Neurology and Neuroscience 1: 59
13. Elsworth JD, Deutch AY, Redmond DE, Jr., Sladek JR, Jr., Roth RH (1990) MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulated cortex of the primate. Neuroscience Letters 114: 316-322 (Pubitemid 20205155)
14. Elsworth JD, Deutch AY, Redmond DE, Jr., Sladek JR, Jr., Roth RH (1990) MPTPinduced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Research 513: 320-324 (Pubitemid 20132272)
15. Schneider JS, Unguez G, Yuwiler A, Berg SC, Markham CH (1988) Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Brain 111 ( Pt 6): 1265-1285 (Pubitemid 19028453)
16. Brooks BA, Eidelberg E, Morgan WW (1987) Behavioral and biochemical studies in monkeys made hemiparkinsonian by MPTP. Brain Res 419: 329-332 (Pubitemid 18089555)
17. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 39: 7-16 (Pubitemid 16090932)
18. Togasaki DM, Hsu A, Samant M, Farzan B, DeLanney LE, Langston JW, Di Monte DA, Quik M (2005) The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods 145: 159-166 (Pubitemid 40732442)
19. Saiki H, Hayashi T, Takahashi R, Takahashi J (2010) Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease. J Neurosci Methods 190: 198-204
20. Schwab RS, England AC, Jr. (1969) Projection techniques for evaluating surgery in Parkinson's disease. In: Gillingham F, Donaldson I (eds) Third Symposium on Parkinson's Disease. E. and S. Livingstone, Edinburgh, Scotland, pp 152-157
21. Fahn S, Elton R, and members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Goldstein M, Calne C (eds) Recent Developments in Parkinson's Disease. Macmillan, Florham Park, NJ, pp 153-163
22. Kurlan R, Kim MH, Gash DM (1991) Oral levodopa dose-response study in MPTPinduced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 6: 111-118
23. Kurlan R, Kim MH, Gash DM (1991) The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys. Ann Neurol 29: 677-679
24. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16: 418-427 (Pubitemid 23292096)
25. Smith RD, Zhang Z, Kurlan R, McDermott M, Gash DM (1993) Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52: 7-16 (Pubitemid 23026601)
26. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284: 299-307
27. Schneider JS, Lidsky TI, Hawks T, Mazziotta JC, Hoffman JM (1995) Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. Brain Res 672: 112-117
28. Papa SM, Chase TN (1996) Levodopainduced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39: 574-578
29. Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE (2000) Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 96: 71-76 (Pubitemid 30125866)
30. Altman J (1974) Observational study of behavior: Sampling methods. Behavior 49: 222-267
31. SAS Institute I (1988) SAS/STAT User's Guide. SAS Institute, Inc., Cary, NC
32. SAS Institute (1988) SAS/STAT User's Guide. SAS Institute, Inc., Cary, NC
33. Taylor JR, Elsworth JD, Sladek JR, Jr., Roth RH, Redmond DE, Jr. (1994) Behavioral effects of MPTP administration in the vervet monkey: a primate model of Parkinson's disease. In: Woodruff ML, Nonneman AJ (eds) Toxin-Induced Models of Neurological Disorders. Plenum Press, New York, pp 139-174
34. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17: 427-442
35. Fahn S, Elton R, Committee amotUD (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden C, Goldstein M, Calne C (eds) Recent Developments in Parkinson's Disease. Macmillan, Florham Park, NJ, pp 153-163
36. Baulu J, Redmond DE, Jr. (1978) Some sampling considerations in the quantitation of monkey behavior under field and captive conditions. Primates 19: 391-399
37. Service USPH (1985) Guide for the Care and Use of Animals. U.S. Government Printing Office, Washington D.C.
38. Winer BJ (1971) Statistical Principles in Experimental Design. McGraw-Hill Book Company, New York
39. Ueki A, Chong PN, Albanese A, Rose S, Chivers JK, Jenner P, Marsden CD (1989) Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology 28: 1089-1097 (Pubitemid 19254403)
40. Hurley PJ, Elsworth JD, Whittaker MC, Roth RH, Redmond DE, Jr (2011). Aged monkeys as a partial model for Parkinson's disease. Pharmacology, biochemistry, and behavior 99: 324-332
41. Bachevalier J, Landis LS, Walker LC, Brickson M, Mishkin M, Price DL, Cork LC (1991) Aged monkeys exhibit behavioral deficits indicative of widespread cerebral dysfunction. Neurobiol Aging 12: 99-111
42. Irwin I, DeLanney LE, McNeill T, Chan P, Forno LS, Murphy GM, Jr., Di Monte DA, Sandy MS, Langston JW (1994) Aging and the nigrostriatal dopamine system: a nonhuman primate study. Neurodegeneration 3: 251-265
43. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, Holden JE, Kordower JH (1998) Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401: 253-265 (Pubitemid 28481965)
44. Zhang Z, Andersen A, Smith C, Grondin R, Gerhardt G, Gash D (2000) Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. J Gerontol A Biol Sci Med Sci 55: B473-480 (Pubitemid 32010283)
45. Elsworth JD, Taylor JR, Sladek JR, Jr., Collier TJ, Redmond DE, Jr., Roth RH (2000) Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95: 399-408
46. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, et al (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90: 11965-11969 (Pubitemid 24008761)
47. al-Tikriti MS, Zea-Ponce Y, Baldwin RM, Zoghbi SS, Laruelle M, Seibyl JP, Giddings SS, Scanley BE, Charney DS, Hoffer PB, et al. (1995) Characterization of the dopamine transporter in nonhuman primate brain: homogenate binding, whole body imaging, and ex vivo autoradiography using (125I) and (123I)IPCIT. Nucl Med Biol 22: 649-658
48. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C, et al. (1995) Decreased single-photon emission computed tomographic (123I)beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38: 589-598
49. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J (2001) (123I) beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57: 2089-2094 (Pubitemid 33126879)
50. Sladek JR, Jr., Redmond DE, Jr., Collier TJ, Haber SN, Elsworth JD, Deutch AY, Roth RH (1987) Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. Progress In Brain Research 71: 309-323 (Pubitemid 18041352)
51. Redmond DE, Jr., Naftolin F, Collier TJ, Leranth C, Robbins RJ, Sladek CD, Roth RH, Sladek JR, Jr. (1988) Cryopreservation, culture, and transplantation of human fetal mesencephalic tissue into monkeys. Science 242: 768-771
52. Elsworth JD, Redmond DE, Jr., Sladek JR, Jr., Deutch AY, Collier TJ, Roth RH (1989) Reversal of MPTP-induced parkinsonism in primates by fetal dopamine cell transplants. In: Franks AJ, Ironside JW, Mindham RHS, Smith RJ, Spokes EGS, Winlow W (eds) Function and Dysfunction of the Basal Ganglia. Manchester University Press, New York, pp 161-180
53. Taylor J, Elsworth J, Roth R, Sladek J, Jr., Collier T, Redmond D, Jr. (1991) Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: A comparison with other types of grafts as controls. Experimental Brain Research 85: 335-348
54. Redmond DE, Jr., Roth RH, Elsworth JD, Smith E, Al-Tikriti M, Taylor JR, Sladek JR, Neumeyer RB, Innis RB, Hoffer P (1993) SPECT studies with CIT provide reliable estimates of striatal dopamine (DA) depletion corresponding to the degree of parkinsonism and identify dopamine grafts in vivo. American College of Neuropsychopharmacology Abstracts: 131
55. Redmond DE, Jr., Sladek JR, Jr., Collier TJ, Elsworth JD, Spencer D, Naftolin F, Leranth C, Robbins RJ, Marek KL, Bunney BS, Roth RH (1993) Impact of fetal age on mesencephalic graft survival in monkeys and humans. Neuroscience Abstracts 19: 864
56. Sladek JR, Jr., Elsworth JD, Roth RH, Evans LE, Collier TJ, Cooper SJ, Taylor JR, Redmond DE, Jr. (1993) Fetal dopamine cell survival after transplantation is dramatically improved at a critical donor gestational age in nonhuman primates. Experimental Neurology 122: 16-27 (Pubitemid 23242267)
57. Elsworth JD, Al-Tikriti MD, Sladek JR, Jr., Taylor JR, Innis RB, Redmond DE, Jr., Roth RH (1994) Novel radioligands for the dopamine transporter demonstrate the presence of intrastriatal nigral grafts in the MPTPtreated monkey: correlation with improved behavioral function. Exp Neurol 126: 300-304 (Pubitemid 24182051)
58. Sladek J, Jr., Elsworth J, Taylor J, Roth R, Redmond D, Jr. (1995) Techniques for neural transplantation in non-human primates. In: Ricordi C (ed) Methods in Cell Transplantation. R.G. Landes, Austin, TX, pp 391-408
59. Taylor JR, Elsworth JD, Sladek JR, Jr., Collier TJ, Roth RH, Redmond DE, Jr. (1995) Sham surgery does not ameliorate MPTP-inducedbehavioral deficits in monkeys. Cell Transplantation 4: 13-26
60. Leranth C, Sladek J, Jr., Roth R, Redmond D, Jr. (1998) Efferent synaptic connections of dopaminergic neurons grafted into the caudate nucleus of experimentally induced parkinsonian monkeys are different from those of control animals. Experimental Brain Research 123: 323-333 (Pubitemid 28526354)
61. Sladek JR, Jr., Collier TJ, Elsworth JD, Roth RH, Taylor JR, Redmond DE, Jr. (1998) Intrastriatal grafts from multiple donors do not result in a proportional increase in survival of dopamine neurons in nonhuman primates. Cell Transplant 7: 87-96. (Pubitemid 28182745)
62. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE, Jr. (2000) Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 20: 8604-8609.
63. Sladek JR, Collier T, Bundock E, Roth RH, Elsworth JD, Taylor J, Redmond DE, Jr (2001) Striatal grafts direct the growth of fibers from co-grafted and host dopaminergic neurons in monkey. American Society of Neural Transplantation and Repair 8: 34
64. Collier TJ, Sortwell CE, Elsworth JD, Taylor JR, Roth RH, Sladek JR, Jr., Redmond DE, Jr (2002) Embryonic ventral mesencephalic grafts to the substantia nigra of MPTPtreated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease. J. Comp. Neurol. 442: 320-330 (Pubitemid 34027514)
65. Elsworth JD, Redmond DE, Jr., Leranth C, Bjugstad KB, Sladek JR, Jr., Collier TJ, Foti SB, Samulski RJ, Vives KP, Roth RH (2008) AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. Exp Neurol 211: 252-258
66. Brunet JF, Redmond DE, Jr., Bloch J (2009) Primate adult brain cell autotransplantation, a pilot study in asymptomatic MPTP treated monkeys. Cell Transplant
67. Redmond DE, Jr., Elsworth JD, Roth RH, Leranth C, Collier TJ, Blanchard B, Bjugstad KB, Samulski RJ, Aebischer P, Sladek JR, Jr. (2009) Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF. J Comp Neurol 515: 31-40
68. Reitan RM, Boll TJ (1971) Intellectual and cognitive functions in Parkinson's disease. J. Consulting and Clinical Psychology 37
69. Loranger AW, Goodell H, McDownell FH, Lee JE, Sweet RD (1972) Intellectual impairment in Parkinson's syndrome. Brain 95: 405-412
70. Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson's disease. Brain 106: 257-270 (Pubitemid 13098511)
71. Taylor AE, Saint-Cyr JA, Lang AE (1986) Frontal dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain 109: 845-883 (Pubitemid 17175608)
72. Sass KJ, Buchanan CP, Westerveld M, Marek KL, Farhi A, Robbins RJ, Naftolin F, Vollmer TL, Leranth C, Roth RH, et al (1995) General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Archives of Neurology 52: 680-686
73. Piaget J (1954) Construction of reality in the child. Basic Books, New York
74. Diamond A (1989) Retrieval of an object from an open box: The development of visual-tactile control of reaching in the first year of life. Monographs of the Society for Research in Child Development
75. Diamond A (1989) Frontal Lobe Involvement in Cognitive Changes During the First Year of Life. Aldine, New York
76. Taylor JR, Elsworth JD, Roth RH, Collier TJ, Sladek JR, Redmond DE, Jr. (1990) Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. In: Richards SJ, Dunnett SB (eds) Progress in Brain Research, vol 82. Elsevier, Amsterdam, pp 543-559 (Pubitemid 20299656)
77. Taylor JR, Elsworth JD, Roth RH, Sladek JR, Jr., Redmond DE, Jr. (1990) Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. Brain 113: 617-637 (Pubitemid 20222322)
78. Taylor JR, Roth RH, Sladek JR, Jr., Redmond DE, Jr. (1990) Cognitive and motor deficits in the performance of an object retrieval task with barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: Longterm performance and effect of transparency of the barrier. Behavioral Neuroscience 104: 564-576 (Pubitemid 20292783)
79. Korosec M, Zidar I, Reits D, Evinger C, Vanderwerf F (2006) Eyelid movements during blinking in patients with Parkinson's disease. Mov Disord 21: 1248-1251 (Pubitemid 44336621)
80. Agostino R, Bologna M, Dinapoli L, Gregori B, Fabbrini G, Accornero N, Berardelli A (2008) Voluntary, spontaneous, and reflex blinking in Parkinson's disease. Mov Disord 23: 669-675
81. Elsworth JD, Lawrence MS, Roth RH, Taylor JR, Mailman RB, Nichols DE, Lewis MH, Redmond DE, Jr. (1991) D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J. of Pharmacology and Experimental Therapeutics 259: 595-600
82. Lawrence MS, Redmond DE, Jr. (1991) MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys. Pharmacology, Biochemistry and Behavior 38: 869-874
83. Taylor JR, Elsworth JD, Lawrence MS, Sladek JR, Jr., Roth RH, Redmond DE, Jr. (1999) Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTPtreated monkeys. Exp Neurol 158: 214-220 (Pubitemid 29344334)
84. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 15: 459-466 (Pubitemid 30333216)
85. Langston JW, Quik M, Petzinger G, Jakowec M, Di Monte DA (2000) Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 47: S79-89 (Pubitemid 30192013)
86. Petzinger GM, Quik M, Ivashina E, Jakowec MW, Jakubiak M, Di Monte D, Langston JW (2001) Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate. Mov Disord 16: 202-207 (Pubitemid 36049966)
87. Redmond DE, Jr., Vinuela A, Kordower JH, Isacson O (2008) Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis 29: 103-116 (Pubitemid 350186113)
88. Isacson O, Kordower, J., Vinuela, A, Redmond, DE, Jr. (2011) Cell transplant consortium studies of impact of fetal tissue grafting on the induction of dyskinesia in MPTP treated monkeys. In preparation.
89. Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, Jacobowitz DM (1986) Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 382: 360-364 (Pubitemid 16001743)
90. Annett LE, Rogers DC, Hernandez TD, Dunnett SB (1992) Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 115 ( Pt 3): 825-856
91. Schneider JS, McLaughlin WW, Roeltgen DP (1992) Motor and nonmotor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion. Neurology 42: 1565-1572
92. Eberling JL, Jagust WJ, Taylor S, Bringas J, Pivirotto P, VanBrocklin HF, Bankiewicz KS (1998) A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. Brain Res 805: 259-262 (Pubitemid 29005142)
93. Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS (2003) Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front Biosci 8: a155-166 (Pubitemid 39069955)
94. Bohn MC, Marciano F, Cupit L, Gash DM (1988) Recovery of dopaminergic fibers in striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse is enhanced by grafts of adrenal medulla. Prog Brain Res 78: 535-542 (Pubitemid 19023585)
95. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103: 987-1041 (Pubitemid 26383833)
96. Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50: 55-66 (Pubitemid 27055928)
97. Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M (2009) Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). Postgrad Med 121: 176-196
98. Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE (1997) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 766: 107-112 (Pubitemid 27431440)
99. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21: 6853-6861 (Pubitemid 32781128)
100. Hiral S (1968) Ageing of the substantia nigra. Adv Neurol Sci 7: 12845-12849
101. Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm 45: 81-105 (Pubitemid 9173404)
102. Calne DB, Peppard RF (1987) Aging of the nigrostriatal pathway in humans. Can J Neurol Sci 14: 424-427 (Pubitemid 17147626)
103. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301
104. Felten DL, Felten SY, Steece-Collier K, Date I, Clemens JA (1992) Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies. Ann Neurol 32 Suppl: S133-136
105. Agid Y, Hirsch E, Anglade P, Michel P, Brugg B, Ruberg M (1996) Aging, disease and death of nerve cells. Acta Neurol Belg 96: 219-223 (Pubitemid 126447536)
106. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN (2002) Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism Relat Disord 9: 103-110 (Pubitemid 35447536)
107. Chu Y, Kompoliti K, Cochran EJ, Mufson EJ, Kordower JH (2002) Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 450: 203-214 (Pubitemid 34809993)
108. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515-517
109. Burton A (2006) mtDNA deletions associated with ageing and PD. Lancet Neurol 5: 477
110. Chu Y, Kordower JH (2007) Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis 25: 134-149 (Pubitemid 44765223)
111. Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, Sortwell C, Bakay RA, Sladek JR, Jr., Kordower JH (2007) Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 26: 56-65 (Pubitemid 46436486)
112. Hawkes CH (2008) Parkinson's disease and aging: same or different process? Mov Disord 23: 47-53 (Pubitemid 351281217)
113. Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792: 651-663
114. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334: 71-76 (Pubitemid 26017932)
115. Emborg ME (2007) Nonhuman primate models of Parkinson's disease. Ilar J 48: 339-355 (Pubitemid 350194367)
116. Jenner P (2003) The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat Disord 9: 131-137 (Pubitemid 36173561)
117. Jenner P (2003) The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 61: S4-11 (Pubitemid 37151640)
118. Orr CF, Rowe DB, Halliday GM (2002) An inflammatory review of Parkinson's disease. Prog Neurobiol 68: 325-340 (Pubitemid 36071510)
119. Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC (2005) Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann N Y Acad Sci 1057: 296-318 (Pubitemid 43211642)
120. Carvey PM, Punati A, Newman MB (2006) Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 15: 239-250 (Pubitemid 43726183)
121. Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34: 55-65
122. Olanow CW, Kordower JH (2009) Modeling Parkinson's disease. Ann Neurol 66: 432-436
123. Horowitz MP, Greenamyre JT (2010) Geneenvironment interactions in Parkinson's disease: the importance of animal modeling. Clin Pharmacol Ther 88: 467-474
124. Jenner P (2009) From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 4: S18-23